TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31759771
Drug: Domperidone suspension
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone suspension 20 mg/20 ml q6h for 24 h
Study: 19581631
Drug: Stepped-dose efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stepped-dose efavirenz (200 mg/d on days 1-6, 400 mg/d on days 7-13, 600 mg/d from day 14)
Study: 19581631
Drug: Full-dose efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Full-dose efavirenz (600 mg/d from day 1)
Study: 19581631
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Stepped-dose and Full-dose)
Study: 17472846
Drug: Heparin-coated polyacrylonitrile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated polyacrylonitrile membrane (AN69ST)
Study: 7648641
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis during perioperation
Study: 7648641
Drug: Routine use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine use of antibiotics as usual (Control)
Study: 2686258
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg isosorbide dinitrate (ISDN)
Study: 7957511
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg isosorbide dinitrate (ISDN)
Study: 2686258
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg isosorbide dinitrate (ISDN)
Study: 2686258
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg ISDN + 25 mg gallopamil (G)
Study: 2686258
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg ISDN + 50 mg gallopamil (G)
Study: 2686258
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg ISDN + 80 mg propranolol (P)
Study: 2686258
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ISDN + 25 mg gallopamil (G)
Study: 2686258
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ISDN + 50 mg gallopamil (G)
Study: 2686258
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ISDN + 80 mg propranolol (P)
Study: 2686258
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ISDN + 25 mg gallopamil (G)
Study: 2686258
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ISDN + 50 mg gallopamil (G)
Study: 2686258
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ISDN + 80 mg propranolol (P)
Study: 7388119
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg pyridoxine per day
Study: 7388119
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg pyridoxine per day
Study: 7388119
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g pyridoxine per day
Study: 27913066
Drug: Betamethasone‐17‐valerate cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone‐17‐valerate cream
Study: 27913066
Drug: Essex® cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essex® cream (moisturizer)
Study: 22676330
Drug: FREMS and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FREMS and topical treatment (Group A)
Study: 22676330
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment alone (Group B)
Study: 18778138
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy treatment for alcohol dependence
Study: 15641125
Drug: Methylphenidate (5
Normalized name: methylphenidate (50/50 release) 20 mg/24 hr oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (5 mg/day increasing to 20 mg/day)
Study: 15641125
Drug: Sertraline (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (25 mg/day increasing to 100 mg/day)
Study: 9915366
Drug: Intrathecal baclofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal baclofen (ITB) 50 microg bolus injection followed by continuous infusion of 302 microg per day
Study: 7035598
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of stilboestrol and ethisterone therapy during pregnancy
Study: 7035598
Drug: Inactive tablet
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive tablet (control)
Study: 23578678
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose CTP (80 mAs)
Study: 23578678
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose CTP (100 mAs)
Study: 11337737
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of AWL with low-pressure pneumoperitoneum (3 to 4 mm Hg)
Study: 9429053
Drug: self‐administered subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: self‐administered subcutaneous recombinant human erythropoietin (rhEPO) at a dose of 60 U.kg‐1 BW three times a week and oral iron treatment (ferrofumarate)
Study: 9429053
Drug: self‐administered subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: self‐administered subcutaneous recombinant human erythropoietin (rhEPO) and oral iron treatment
Study: 9429053
Drug: self‐administered subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: self‐administered subcutaneous recombinant human erythropoietin (rhEPO)
Study: 7939760
Drug: 135 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 135 mg/m2 given as a single dose over 1 hour
Study: 7939760
Drug: 135 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 135 mg/m2 given in divided hourly daily doses for 3 days
Study: 26214630
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy with 4 cycles of carboplatin and etoposide followed by conformal 3-dimensional (3D) radiotherapy (RT)
Study: 26214630
Drug: Concurrent chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemotherapy with cisplatin and etoposide and conformal RT, followed by two cycles of consolidation chemotherapy with carboplatin and etoposide
Study: 19011437
Drug: Bilastine 80
Normalized name: bilastine
DrugBank: Bilastine (DB11591)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Bilastine 80 mg
Study: 12430112
Drug: Fentanyl 10
Normalized name: FENTANYL 100MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 10 micro g added to 0.5% hyperbaric ropivacaine 18 mg
Study: 12430112
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 0.2 mL added to 0.5% hyperbaric ropivacaine 18 mg
Study: 8942891
Drug: Adjunctive subconjunctival
Normalized name: lincomycin
DrugBank: Lincomycin (DB01627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive subconjunctival mitomycin C (MMC)
Study: 8942891
Drug: No adjunctive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjunctive mitomycin C (Control)
Study: 31780589
Drug: Clinically-supervised gradual
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinically-supervised gradual reduction of antipsychotic medication leading to discontinuation when possible
Study: 31780589
Drug: Clinically-supervised gradual
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinically-supervised gradual reduction of antipsychotic medication
Study: 27684802
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (DEX) at 4.33 μg/kg combined with sufentanil (SUF) at 3.0 μg/kg via PCIA
Study: 22497754
Drug: Lamotrigine extended-release
Normalized name: Lamotrigine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine extended-release (LTG XR)
Study: 12582834
Drug: Prazosin (alpha(1)-adrenergic
Normalized name: prazosin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (alpha(1)-adrenergic antagonist), single oral dose
Study: 11187913
Drug: Therapy based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy based on the Berlin‐Frankfurt‐Münster 76/79 study
Study: 1625101
Drug: rHuEPO, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO, 400 IU/kg three times a week plus iron, 20 mg/wk intravenously
Study: 6387184
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg trimethoprim (20 patients)
Study: 28980368
Drug: Target dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target dose enalapril (20 mg/day)
Study: 28980368
Drug: Below-target dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Below-target dose enalapril (5-10 mg/day)
Study: 28980368
Drug: Target dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target dose placebo (20 mg/day)
Study: 28980368
Drug: Below-target dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Below-target dose placebo (5-10 mg/day)
Study: 28980368
Drug: Target dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target dose enalapril vs. below-target dose enalapril
Study: 11959616
Drug: Water treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water treatment with praziquantel
Study: 7503194
Drug: Oral terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbutaline (n = 50)
Study: 7503194
Drug: Oral terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbutaline (n = 41)
Study: 7503194
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no oral terbutaline, n = 53)
Study: 7503194
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no oral terbutaline, n = 40)
Study: 2188763
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg APD intravenously
Study: 25563826
Drug: Furosemide (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (0.2 mg/kg/h, up to 0.8 mg/kg/h)
Study: 25563826
Drug: Ethacrynic Acid
Normalized name: Ethacrynic Acid
DrugBank: Etacrynic acid (DB00903)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethacrynic Acid (0.2 mg/kg/h, up to 0.8 mg/kg/h)
Study: 23975856
Drug: Radiofrequency (RF)
Normalized name: Aminosyn-RF 5.2 %, Sulfite-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiofrequency (RF) shrinkage treatment
Study: 21120480
Drug: Cediranib administered
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib administered in fed state
Study: 21120480
Drug: Cediranib 30
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib 30 mg/day (fixed-dose)
Study: 21120480
Drug: Cediranib administered
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cediranib administered in fasted state
Study: 19434533
Drug: Postoperative intraperitoneal
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative intraperitoneal chemotherapy combined with systemic chemotherapy
Study: 19434533
Drug: Intraperitoneal chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal chemotherapy regimen with Oxaliplatin
Study: 19434533
Drug: Intraperitoneal chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal chemotherapy regimen with Cisplatin
Study: 10692004
Drug: Encapsulated fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated fish oil (FO) providing 2.1 g eicosapentaenoic acid (EPA) plus 1.1 g docosahexaenoic acid (DHA) per day for 12 weeks
Study: 3896665
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg dimetophrine
Study: 26899862
Drug: Perineural dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perineural dexamethasone (8 mg mixed with ropivacaine)
Study: 25514302
Drug: Lamivudine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine (100 mg daily)
Study: 17638396
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch (16.6mg nicotine/patch) in former smokers (group 2)
Study: 16054963
Drug: Contraceptive patch
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive patch (n = 846)
Study: 16054963
Drug: Oral contraception
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraception (OC) (n = 643)
Study: 12134249
Drug: Intranasal interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal interferon (IFN)‐alpha2b (6 x 10(6) U every 12 h x 3) plus oral chlorpheniramine (12 mg extended release) and ibuprofen (400 mg) every 12 h for 4.5 days (n=59 subjects)
Study: 12134249
Drug: Intranasal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal placebo plus oral chlorpheniramine and ibuprofen (n=61 subjects)
Study: 12134249
Drug: Intranasal and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal and oral placebos (n=30 subjects)
Study: 11756911
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of music and patient-controlled sedation with a mixture of propofol and alfentanil
Study: 11756911
Drug: Music alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music alone with diazemuls and meperidine administered intravenously if requested
Study: 11756911
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of music and patient-controlled sedation
Study: 2904237
Drug: Daily treatment
Normalized name: BENZOYL PEROXIDE 2.5 g in 100 g TOPICAL GEL [Acne defense Daily Treatment Serum Merle Norman]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily treatment with streptomycin, isoniazid, rifampin, and pyrazinamide for 2 months (2SHRZ) followed by 3‐times‐weekly isoniazid and rifampin (H3 R3)
Study: 2904237
Drug: Daily treatment
Normalized name: BENZOYL PEROXIDE 2.5 g in 100 g TOPICAL GEL [Acne defense Daily Treatment Serum Merle Norman]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily treatment with isoniazid, rifampin, and pyrazinamide for 1 month (1SHRZ) followed by 3‐times‐weekly isoniazid and rifampin (H3 R3)
Study: 2904237
Drug: Daily treatment
Normalized name: BENZOYL PEROXIDE 2.5 g in 100 g TOPICAL GEL [Acne defense Daily Treatment Serum Merle Norman]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily treatment with isoniazid, rifampin, and pyrazinamide for 2 months without streptomycin (2HRZ) followed by 3‐times‐weekly isoniazid and rifampin (H3 R3)
Study: 2904237
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with drug‐susceptible strains pretreatment
Study: 2904237
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with strains resistant to isoniazid, streptomycin, or both drugs pretreatment
Study: 29189607
Drug: K12 (2.5 × 10(9)
Normalized name: povidone K12
Approvals — FDA: no, EMA: no, PMDA: no
Description: K12 (2.5 × 10(9) cfu per lozenge)
Study: 26852498
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of intermittent pneumatic compression, kinesio-taping, and underwater massage shower
Study: 18055869
Drug: Fludarabine (single-agent)
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine (single-agent)
Study: 18055869
Drug: Fludarabine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine monotherapy
Study: 18055869
Drug: DAT status
Normalized name: Statuss Green Reformulated Jan 2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAT status at initiation of therapy
Study: 16476713
Drug: Celecoxib (CBX)
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib (CBX) 200 mg/24 h
Study: 16476713
Drug: Aceclofenac (ACF)
Normalized name: aceclofenac
DrugBank: Aceclofenac (DB06736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aceclofenac (ACF) 100 mg/12 h
Study: 11099750
Drug: INN 00835
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: INN 00835 (0.2 mg/kg subcutaneously for 5 consecutive days)
Study: 9368550
Drug: t-PA treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: t-PA treatment
Study: 1311535
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of mivacurium at a rate of 6 +/- 2 micrograms.kg‐1.min‐1 after an initial bolus of 2 x ED95.
Study: 1311535
Drug: Repeated injection
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated injection of mivacurium at 0.6 x ED95 whenever twitch tension recovered to 25% of control.
Study: 1311535
Drug: Neostigmine (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine (7 micrograms/kg) administered at 25% twitch recovery in both groups.
Study: 28285208
Drug: Varenicline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline and cognitive-behavioral therapy for smoking cessation
Study: 19387697
Drug: Wallis interspinous
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Wallis interspinous implant (group W)
Study: 16452735
Drug: Enoxaparin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (30 mg, administered subcutaneously twice a day) starting 24-48 hours after blunt trauma
Study: 14747633
Drug: Fluoxetine, Paroxetine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine, Paroxetine, or Sertraline (SSRI antidepressants)
Study: 2441458
Drug: Elmiron 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elmiron 200 mg X 2 daily
Study: 22357109
Drug: Intracoronary abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary abciximab (0.25 mg/kg bodyweight bolus followed by 12 h intravenous infusion at 0.125 μg/kg per min)
Study: 21115882
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg orally twice daily for 9 months
Study: 15893193
Drug: n-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 polyunsaturated fatty acids (PUFAs) 2 g/day
Study: 8661572
Drug: IV butylscopolamine
Normalized name: butylscopolamine
DrugBank: Butylscopolamine (DB09300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV butylscopolamine (20 mg)
Study: 8661572
Drug: Oral dicyclomine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dicyclomine (20 mg)
Study: 30745582
Drug: NK105 (65
Approvals — FDA: no, EMA: no, PMDA: no
Description: NK105 (65 mg/m2)
Study: 30745582
Drug: Paclitaxel (PTX)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel (PTX) (80 mg/m2)
Study: 28407009
Drug: Refractive error
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refractive error treatment coverage in Indigenous Australians
Study: 28407009
Drug: Refractive error
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refractive error treatment coverage in non-Indigenous Australians
Study: 28407009
Drug: Protective factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protective factor for treatment of refractive error in Indigenous Australians
Study: 21852546
Drug: H10407 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H10407 at doses of 10(7) CFU with bicarbonate
Study: 19651565
Drug: Erythropoietin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (300 U/kg or 500 U/kg) administered every other day for 2 weeks
Study: 12413642
Drug: Propranolol and
Normalized name: propranolol and thiazides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol and Atenolol (beta-adrenergic antagonists)
Study: 9366462
Drug: Intramuscular rocuronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular rocuronium (1,000 microg/kg for infants and 1,800 microg/kg for children)
Study: 9366462
Drug: Intravenous rocuronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous rocuronium (not specified in detail)
Study: 3523298
Drug: Pirenzepine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (10 mg e.v./8 hours, starting the day before surgery to 10th day after it)
Study: 3523298
Drug: Void period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Void period (without specific therapy)
Study: 29969209
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist pretreatment for three days
Study: 29969209
Drug: Conventional antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Conventional antagonist protocols
Study: 20056900
Drug: AMG 317
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 317 75 mg
Study: 20056900
Drug: AMG 317
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 317 150 mg
Study: 20056900
Drug: AMG 317
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 317 300 mg
Study: 19343871
Drug: OXY‐TDS administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: OXY‐TDS administration
Study: 15721109
Drug: Drug-eluting stents
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stents (sirolimus and paclitaxel)
Study: 1888632
Drug: Flosequinan (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flosequinan (oral, administered for 14 days)
Study: 30361793
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel application with mock PBM‐LLLT
Study: 30282144
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine 3 ml (Group A)
Study: 30282144
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine 2 ml + physiological saline 1 ml (Group B)